2
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Polycystic Ovary Syndrome
3
Fatty Liver
2
Diabetes Mellitus
2
Thyroid Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Obesity
1
Neoplasms
1
Menstruation Disturbances
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma
1
Iron Overload
1
Hypertriglyceridemia
1
Hyperthyroidism
1
Hemoglobinopathies
1
Graves Disease
1
Glucose Metabolism Disorders
1
Glucose Intolerance
1
Fibrous Dysplasia, Polyostotic
1
Fibrous Dysplasia of Bone
1
Interventions
Cyclophosphamide
413
Methotrexate
250
Cytarabine
235
Vincristine
192
fludarabine phosphate
174
Dexamethasone
171
fludarabine
147
Etoposide
143
Peripheral Blood Stem Cell Transplantation
137
Filgrastim
132
Whole-Body Irradiation
118
Mycophenolic Acid
116
Busulfan
113
Doxorubicin
110
Mercaptopurine
108
Tacrolimus
107
Cyclosporine
95
Radiotherapy
93
Melphalan
93
pegaspargase
90
Rituximab
90
Prednisone
87
Asparaginase
87
Daunorubicin
86
Granulocyte Colony-Stimulating Factor
76
blinatumomab
74
Antilymphocyte Serum
71
Calcium Dobesilate
69
Clofarabine
58
Thiotepa
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Glucose Tolerance Test
×
Clear all
NCT03141398
2017-07-26
CGMs
Hamad Medical Corporation
Withdrawn